Vulvovaginal Candidiasis Management
Diagnosis and First-Line Treatment
- For recurrent vulvovaginal candidiasis (RVVC), defined as three or more symptomatic episodes within 12 months, the recommended treatment is induction therapy with 10-14 days of a topical or oral azole, followed by fluconazole 150 mg once weekly for 6 months as maintenance therapy, as recommended by the Infectious Diseases Society of America 1, 2
- Diagnosis should be confirmed with wet mount preparation using saline and 10% potassium hydroxide to demonstrate yeast or hyphae, checking for normal vaginal pH (<4.5), and obtaining vaginal cultures for definitive identification in negative wet mount cases 2
- First-line treatment options include oral fluconazole 150 mg every 72 hours for 3 doses or topical azole therapy for 10-14 days, with a strength of evidence supporting the effectiveness of these treatments 1, 2
Treatment of Resistant Strains
- For fluconazole-resistant C. albicans, treatment options include boric acid 600 mg intravaginal suppositories daily for 14 days or topical 17% flucytosine cream alone or with 3% amphotericin B cream daily for 14 days (requires compounding) 2, 3
- For non-albicans Candida species (particularly C. glabrata), treatment options include boric acid 600 mg intravaginal suppositories daily for 14 days 2
- Alternative systemic options for resistant strains include itraconazole 200 mg daily for up to 28 days, posaconazole suspension 400 mg twice daily for 3 days, then 400 mg daily for up to 28 days, and voriconazole 200 mg twice daily for 14-21 days, with evidence from the Infectious Diseases Society of America 3 and the European Society of Clinical Microbiology and Infectious Diseases 4
Maintenance Therapy
- Standard maintenance therapy includes fluconazole 150 mg once weekly for 6 months, which achieves control of symptoms in >90% of patients, with a high strength of evidence supporting its effectiveness 1, 2
- Alternative maintenance options (if fluconazole is not feasible) include clotrimazole 200 mg twice weekly or clotrimazole 500 mg vaginal suppository once weekly, with evidence from the Infectious Diseases Society of America 2 and the Centers for Disease Control and Prevention 2
Special Considerations
- Antiretroviral therapy is strongly recommended in addition to antifungal treatment for HIV-positive women, with treatment response rates expected to be identical to HIV-negative women 2, 3
- Evaluate for diabetes or other underlying conditions, and consider HIV testing as immunosuppression can contribute to recurrent infections, with evidence from the Infectious Diseases Society of America 3 and the European Society of Clinical Microbiology and Infectious Diseases 4
Recurrence and Follow-Up
- After completing the 6-month maintenance regimen, approximately 40-50% of women will experience recurrence, highlighting the importance of long-term follow-up and consideration of longer-term suppressive therapy or alternative approaches based on culture and susceptibility testing 1, 2
- For recurrent yeast infection with culture showing Candida albicans resistant to fluconazole, boric acid 600 mg intravaginal suppositories daily for 14 days is the recommended first-line treatment, followed by maintenance therapy with a non-fluconazole agent, as recommended by the Infectious Diseases Society of America 3
- Consider weekly boric acid suppositories for 6 months for patients who respond to boric acid, and intermittent topical therapy (e.g., clotrimazole cream 200 mg twice weekly or clotrimazole vaginal suppository 500 mg once weekly) for at least 6 months for patients who respond to other topical agents, with evidence from the Infectious Diseases Society of America 3 and the Centers for Disease Control and Prevention 2
Severe or Refractory Cases
- For severe or refractory cases that don't respond to the above treatments, consider intravenous echinocandins (caspofungin, micafungin, or anidulafungin), with evidence from the Infectious Diseases Society of America 3 and the European Society of Clinical Microbiology and Infectious Diseases 4
- Amphotericin B deoxycholate (intravenous or oral suspension) is also an option for severe or refractory cases, as recommended by the Infectious Diseases Society of America 3